Biotechnology

A strategic partnership with 5 Horizons Ventures accelerates Marvel Biosciences' novel drug, MB-204, into human trials for autism, Rett syndrome, and more.

A biotech firm is putting genetically engineered probiotics on bar menus. Is this the future of nightlife or a high-tech placebo for the mindful drinker?

A new bispecific antibody aims to treat the 50% of AxSpA patients who find no relief, as Fortitude Biomedicines enters a competitive autoimmune market.

A US-Uruguay collaboration is using novel REJOIN-seq tech to find hidden RNA triggers of lupus, paving the way for safer, non-immunosuppressive drugs.

With new funding led by Telegraph Hill Partners, Kytopen is scaling its Flowfect® tech to make advanced cell therapies faster, cheaper, and more accessible.

A new report reveals a major education gap in obesity care. Informed patients are now demanding options beyond blockbuster drugs like Wegovy and Zepbound.

Life Sciences Ontario's new board appointments signal a strategic shift, bringing in leaders from medtech, agri-tech, pharma, and nuclear isotopes.

AIRNA has dosed the first patient with AIR-001, an RNA-editing drug that could treat both the lung and liver damage of a devastating genetic disease.

Backed by a $41.3M ARPA-H award, SonoNeu is pioneering sonogenetics, a non-invasive therapy using ultrasound to control cells and treat nerve pain.

The firm adds veteran TD Cowen analyst Boris Peaker to deepen its research in oncology and genetic medicines, signaling a major bet on specialized insight.

Avaí Bio and Austrianova are set to present new findings on a novel cell-based therapy designed to produce the 'longevity protein' Klotho.

In a major strategic move, Premier Research appoints Paul Spreen as CCO, signaling a bold push to capture the rebounding biotech market.

A new trial for advanced liver cancer tests visugromab, a drug aiming to overcome immunotherapy resistance and reverse debilitating cancer-related wasting.

A new botanical drug candidate, NFL-102, targets the deep neural roots of addiction, moving beyond symptom management to offer a lasting cure for smokers.

A novel interferon-based therapy from ABION shows promise in preclinical studies, overcoming resistance to current cancer drugs and activating the immune system.

With diagnostic sales fueling a diverse therapeutic arsenal, Telix reaffirms blockbuster guidance and advances pivotal trials for prostate, brain, and kidney cancers.

Decoy Therapeutics touts a revolutionary AI platform for multi-virus drugs, but faces financial hurdles. An upcoming investor event could define its future.

Vyome is set to present promising Phase 2 data for VT-1953, a first-in-class treatment for a debilitating cancer complication with no approved drugs.

In a pivotal move from R&D to commercial scale, Zivo Bioscience partners with industry leader Cyanotech to meet global demand for its unique algal biomass.

Boston's Bio-IT World conference shifts from AI theory to execution, showcasing how the life sciences industry is now deploying AI to accelerate new therapies.